TrialsgrambetaRCTs are beautiful

ATHOS-3

2017

Angiotensin II for the Treatment of High-Output Shock

In 321 patients with catecholamine-resistant vasodilatory shock, synthetic angiotensin II improved MAP response at 3 hours compared with placebo, without proven mortality benefit.

Result

Efficacy: MAP response (≥10 mm Hg or ≥75 mm Hg) at 3 hoursOR 7.95 · P < 0.001

Below 1 favours placebo, above 1 favours synthetic angiotensin II.

Event rates
Absolute difference
46.5 points
NNT
3

Absolute difference and NNT are derived from the event rates.

Also reported: 28-d mortality 46% vs 54% (HR 0.78; p=0.12).

Original publication
Subtopic
Vasopressors
Design
Double-blind RCT
Relevance
Supporting: context rather than must-know.
Source
Khanna A, et al. N Engl J Med. 2017;377(5):419-430.doi 10.1056/NEJMoa1704154

Discussion & critique

FDA-approved 2017 for catecholamine-resistant shock; reserve for refractory cases at experienced centres.